Shenzhen Neptunus Bioengineering Co Ltd
Shenzhen Neptunus Bioengineering Co., Ltd. engages in the research and development, production, and sale of Chinese patent medicines, infusion products, and western medicine preparations in China. The company provides oryzanol tablets, chlorpheniramine maleate tablets, estazolam tablets, and rifampicin capsules, as well as technical support for generic drug quality consistency evaluation and othe… Read more
Shenzhen Neptunus Bioengineering Co Ltd - Asset Resilience Ratio
Shenzhen Neptunus Bioengineering Co Ltd (000078) has an Asset Resilience Ratio of 0.46% as of September 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2001–2024)
This chart shows how Shenzhen Neptunus Bioengineering Co Ltd's Asset Resilience Ratio has changed over time. Compare with other companies' asset resilience ratios.
Liquid Assets Composition Over Time
This chart breaks down Shenzhen Neptunus Bioengineering Co Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CN¥0.00 | 0% |
| Short-term Investments | CN¥125.94 Million | 0.46% |
| Total Liquid Assets | CN¥125.94 Million | 0.46% |
Asset Resilience Insights
- Limited Liquidity: Shenzhen Neptunus Bioengineering Co Ltd maintains only 0.46% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
Shenzhen Neptunus Bioengineering Co Ltd Industry Peers by Asset Resilience Ratio
Compare Shenzhen Neptunus Bioengineering Co Ltd's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Swedish Orphan Biovitrum AB (publ)
PINK:BIOVF |
Drug Manufacturers - Specialty & Generic | -0.02% |
|
Dongwha Pharm.Co.Ltd
KO:000020 |
Drug Manufacturers - Specialty & Generic | 1.92% |
|
Yuhan Corp Preferred
KO:000105 |
Drug Manufacturers - Specialty & Generic | 0.99% |
|
Anhui Fengyuan Pharmaceutical Co Ltd
SHE:000153 |
Drug Manufacturers - Specialty & Generic | 1.81% |
|
Kotra Industries Bhd
KLSE:0002 |
Drug Manufacturers - Specialty & Generic | 9.82% |
|
Yuyu Pharma
KO:000220 |
Drug Manufacturers - Specialty & Generic | 1.74% |
|
Ildong Holdings Co Ltd
KO:000230 |
Drug Manufacturers - Specialty & Generic | 1.57% |
|
Shan Dong Dong-E E-Jiao Co Ltd
SHE:000423 |
Drug Manufacturers - Specialty & Generic | 20.44% |
Annual Asset Resilience Ratio for Shenzhen Neptunus Bioengineering Co Ltd (2001–2024)
The table below shows the annual Asset Resilience Ratio data for Shenzhen Neptunus Bioengineering Co Ltd.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 0.44% | CN¥125.43 Million | CN¥28.80 Billion | -0.17pp |
| 2023-12-31 | 0.60% | CN¥194.41 Million | CN¥32.30 Billion | +0.00pp |
| 2022-12-31 | 0.60% | CN¥217.71 Million | CN¥36.25 Billion | +0.51pp |
| 2021-12-31 | 0.09% | CN¥35.21 Million | CN¥37.60 Billion | -0.51pp |
| 2020-12-31 | 0.60% | CN¥239.48 Million | CN¥39.72 Billion | +0.57pp |
| 2019-12-31 | 0.03% | CN¥13.16 Million | CN¥41.17 Billion | +0.99pp |
| 2018-12-31 | -0.96% | CN¥-393.95 Million | CN¥41.13 Billion | +0.23pp |
| 2017-12-31 | -1.19% | CN¥-367.86 Million | CN¥30.86 Billion | +0.35pp |
| 2016-12-31 | -1.54% | CN¥-256.95 Million | CN¥16.66 Billion | +0.49pp |
| 2015-12-31 | -2.03% | CN¥-259.32 Million | CN¥12.76 Billion | +1.64pp |
| 2014-12-31 | -3.68% | CN¥-353.99 Million | CN¥9.63 Billion | -0.52pp |
| 2013-12-31 | -3.15% | CN¥-252.81 Million | CN¥8.02 Billion | -3.15pp |
| 2012-12-31 | 0.00% | CN¥140.92K | CN¥5.86 Billion | 0.00pp |
| 2011-12-31 | 0.00% | CN¥132.87K | CN¥4.84 Billion | 0.00pp |
| 2010-12-31 | 0.00% | CN¥134.46K | CN¥4.15 Billion | 0.00pp |
| 2009-12-31 | 0.00% | CN¥125.41K | CN¥3.16 Billion | 0.00pp |
| 2008-12-31 | 0.00% | CN¥122.23K | CN¥2.78 Billion | +0.00pp |
| 2007-12-31 | 0.00% | CN¥121.73K | CN¥3.12 Billion | +0.00pp |
| 2006-12-31 | 0.00% | CN¥100.00K | CN¥3.52 Billion | -3.71pp |
| 2005-12-31 | 3.72% | CN¥148.16 Million | CN¥3.99 Billion | -4.21pp |
| 2004-12-31 | 7.92% | CN¥295.35 Million | CN¥3.73 Billion | +7.43pp |
| 2003-12-31 | 0.49% | CN¥19.72 Million | CN¥4.03 Billion | -0.18pp |
| 2002-12-31 | 0.67% | CN¥23.00 Million | CN¥3.43 Billion | -0.44pp |
| 2001-12-31 | 1.11% | CN¥33.87 Million | CN¥3.04 Billion | -- |